FINWIRES · TerminalLIVE
FINWIRES

Ideaya Biosciences' Darovasertib Combination Data Profile is 'Highly Compelling,' Wedbush Says

By

Ideaya Biosciences' (IDYA) darovasertib plus crizotinib combination's overall data profile is "highly compelling" and data-to-date supports accelerated approval, Wedbush said in a Tuesday note.

The company plans to submit its new drug application for darovasertib in H2 and has announced alignment with the US Food and Drug Administration to review the NDA under the real-time oncology review program, Wedbush noted.

Outside of darovasertib, Wedbush said it is looking forward to a clinical update from ongoing Chinese studies investigating IDE849 by partner Jiangsu Hengrui at a medical conference in H2, as well as registrational trial initiations in 2027.

"We remain excited for the extensive clinical development across pipeline assets, as well as a nearing potential approval for darovasertib," Wedbush analysts said.

The brokerage maintained the company's outperform rating with a $58 price target.

Price: $28.01, Change: $-0.89, Percent Change: -3.08%

Related Articles

Wire

IAC Q1 Loss Narrows, Revenue Falls; Shares Drop After Hours

IAC (IAC) reported a Q1 loss late Monday of $0.94 per diluted share, narrowing from the loss of $2.64 a year earlier.Analysts polled by FactSet expected a loss of $0.37.Revenue in the three months ended March 31 fell to $422.9 million from $481.7 million a year earlier.Analysts surveyed by FactSet expected $520.3 million.IAC shares fell 8.6% in after-hours trading.

$IAC
Wire

Vornado Realty Trust Q1 Non-GAAP FFO, Revenue Fall; Shares Drop After Hours

Vornado Realty Trust (VNO) reported Q1 non-GAAP funds from operations late Monday of $0.52 per diluted share, down from $0.63 a year earlier.Analysts polled by FactSet expected $0.51.Revenue in the three months ended March 31 fell to $459.1 million from $461.6 million a year earlier.Analysts surveyed by FactSet expected $431.7 million.Vornado shares fell 3% in after-hours trading.

$VNO
Wire

GeneDx Q1 Swings to Adjusted Loss, Revenue Rises; 2026 Revenue Guidance Lowered; Shares Fall

GeneDx (WGS) reported Monday Q1 adjusted loss of $0.28 per diluted share, swinging from an adjusted earnings of $0.31 a year earlier.Analysts polled by FactSet expected loss of $0.02.Revenue for the quarter ended March 31 was $102.3 million, up from $87.1 million a year earlier.Analysts surveyed by FactSet expected $112.5 million.For Q2, the company expects revenue of $110 million to $112 million. Analysts expect $130.3 million.The company now expects 2026 revenue of $475 million to $490 million, down from $540 million to $555 million expected earlier. Analysts expect $550.0 million.Shares of the company were down over 45% during after-hours activity.

$WGS